Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.
In Ho JungJung-Ho YunSung Jin KimJaewoo ChungSang Koo LeePublished in: Korean journal of neurotrauma (2023)
Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.
Keyphrases
- traumatic brain injury
- atrial fibrillation
- severe traumatic brain injury
- global health
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- mild traumatic brain injury
- venous thromboembolism
- clinical practice
- peritoneal dialysis
- prognostic factors
- social media
- health information
- optical coherence tomography